Karolinska Development – Q4 and 2015 Year-End Report – February 2016

23.2.2016 08:00 | NASDAQ OMX


Jim Van heusden, CEO, comments: “During the course of 2015 we have made significant progress in executing our new strategy which is designed to transform Karolinska Development into a successful Nordic Venture Capital company delivering attractive returns to our shareholders.In 2015 we have focused our portfolio and streamlined our own organization accordingly I look forward to updating you on our progress in the course of 2016 when we will look to build future value by making new investments.”

2015 – Full Year Highlights

  • Jim Van heusden appointed CEO in March 2015

  • Launched new strategy focused on transforming Karolinska Development into a leading Nordic Venture Capital Company

  • New organizational structure put in place to support venture capital strategy

  • Modified deal flow agreement with Karolinska Institutet Holding AB (KIHAB) will allow Karolinska Development to invest in more mature companies and create a more balanced Nordic-centric investment portfolio

  • Streamlined the Karolinska Development portfolio to allow resources to be focused on those companies with the best chances of delivering attractive returns to shareholders

  • Adoption of a more representative approach to reporting the fair value in line with  the International Private Equity and Venture Capital (IPEV) valuation guidelines

  • Total of SEK 204 million invested in portfolio companies with SEK 131 million coming from Karolinska Development and SEK 73 million from external investors. This is in line with Karolinska Development’s new approach of attracting third party investors to support the development of its portfolio companies.  Another SEK 70 million was raised by third-party syndicates for divested companies Pharmanest, XSpray Microparticles and Athera Biotechnologies.

  • Current level of funding provides sufficient runway to execute its strategy and to unlock the potential value of its portfolio

Q4 Highlights

  • The difficult market environment has also impacted our portfolio and resulted in a non-realized decrease of the Fair Value in line with our valuation guidelines. Total Fair Value of the portfolio at year end was SEK 591.7 million, a decrease of SEK 130.8 million compared to the end of third quarter. Net Fair Value of the portfolio at year end was SEK 267.7 million, a decrease of SEK 83.3 million compared to the end of the third quarter

  • Continuing to execute our strategy, which is focused on transforming Karolinska Development into a leading Nordic Venture Capital Company

  • Karolinska Development and Karolinska Institutet Holding AB (KIHAB) announced the signing of a new non-exclusive deal flow agreement in December. This new agreement will allow Karolinska Development to invest in more mature companies and increase its focus on building a more balanced investment portfolio by sourcing opportunities from both KI and other academic institutions across the Nordic region

  • In December, the Company appointed Viktor Drvota, M.D. PhD as Chief Investment Officer. Dr Drvota is an experienced life science investor and joins Karolinska Development from SEB Venture Capital, where he has been Head of Life Science since 2002. At the same time it was announced that Terje Kalland, M.D. PhD, the Company’s Deputy Chief Executive Officer and Chief Scientific Officer, would retire from both positions effective December 31, 2015

  • Further focusing of the investment portfolio with the divestment of the Company’s entire shareholding in Athera Biotechnologies AB to a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Industrifonden in an earn-out agreement

Portfolio Developments – Q4 Highlights

  • Dilaforette initiated a Phase II clinical trial in October with sevuparin in patients with sickle-cell disease (SCD) experiencing a vaso-occlusive crisis. The trial results are anticipated in H2 2016

  • In October, Promimic signed a strategic agreement with Amendia Inc. (US) that will allow Amendia to develop Promimic’s HAnano Surface technology for use with its patient-focused spinal implants

  • Aprea presented updated preliminary data from its ongoing Phase Ib/II clinical study in ovarian cancer at the European Society for Gynaecological Oncology congress (ESGO) in Nice, France, in October. The data presented suggest that APR-246 can be combined with standard chemotherapy and that preliminary efficacy data indicate that the combination regimen has activity in the treatment of recurrent ovarian cancer

  • OssDsign raised SEK 93 million in an equity financing led by new investors SEB Venture Capital and Fouriertransform with continued investment from Karolinska Development. The proceeds will be used for the market expansion of OssDsign’s product line of unique craniofacial implants

Post period events

  • In January, Akinion Pharmaceuticals AB, announced the appointment of Dr Richard Jones as Chief Executive Officer. Dr Jones recently served at Novartis and GSK as VP, Global Haematology Medicines Commercialization Leader

  • In January, Promimic announced that its strategic partner Sistema de Implante Nacional (SIN) had initiated the launch of the first dental implant coated with Promimic's implant surface HAnano Surface. The implant was launched at CIOSP (Sao Paolo International Dental Meeting), the second largest dental trade show in the world.

  • In February, Dilaforette signed an agreement with Arabian Gulf University to support the company’s current Phase II clinical trial with sevuparin in patients with SCD

Financial Update

  • Investments in portfolio companies during the fourth quarter amounted to SEK 15.7 million (SEK 27.5 million  2014). A total of SEK 130.8 million was invested in portfolio companies during the course of 2015 (SEK 92.6 million  2014)

  • Net loss amounted to SEK 121.6 million in the fourth quarter (SEK - 46.8 million in the fourth quarter 2014)

  • Cash, cash equivalents and short term liquidity investments decreased by SEK 31.2 million during the fourth quarter and amounted to SEK 297.2 million as of end December 2015. At the end of 2014 cash, cash equivalents and short term liquidity investments amounted to SEK141.3 million

  • The difficult market environment has also impacted our portfolio and resulted in a non-realized decrease of the Fair Value in line with our valuation guidelines. Total Fair Value of the portfolio at year end was SEK 591.7 million, a decrease of SEK 130.8 million compared to the end of third quarter. Net Fair Value of the portfolio at year end was SEK 267.7 million, a decrease of SEK 83.3 million compared to the end of the third quarter

  • Restructured organization is expected to reduce operational cost in 2016 by approximately 30%

Conference Call and Webcast

Please dial in at one of the following numbers a few minutes before the start of the conference call:

  • From Sweden: +46 (0) 8 505 564 74
  • From the US: +1 855 753 22 30
  • From the UK: +44 (0) 20 336 453 74

The presentation will also be webcast and can be accessed from the following web address:

Host: Jim Van heusden, CEO. 

For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: 

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail:

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail:


About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients’ lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of 12 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.

For more information, please visit


One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Novavax' Preclinical Influenza Nanoparticle Study Published in Vaccine23.8.2017 13:00Pressemelding

Novel vaccine candidate, NanoFlu(TM), outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study GAITHERSBURG, Md., Aug.  23, 2017  (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced that data from a preclinical study of its nanoparticle influenza vaccine candidate with its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) have been published in the journal Vaccine. Novavax is developing NanoFlu to protect older adults from seasonal influenza. The manuscript describes the formulation of Novavax' novel seasonal influenza vaccine candidate, NanoFlu, based on the 2017-2018 World Health Organization (WHO) recommended influenza strains. The study, conducted in ferrets, found that NanoFlu induced hemagglutination-inhibition (HAI) and microneutralizing (MN) antibodies against a broad range of influenza subtypes. In a head-to-head comparison against standard-dose and high-do

Crown Bioscience Names Dr. Leon Hall Vice President of Global Scientific Excellence23.8.2017 12:29Pressemelding

SANTA CLARA, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today the appointment of Dr. Leon Hall as Vice President of Global Scientific Excellence. In his new role, Dr. Hall will be responsible for overseeing global R&D programs and advancing Crown Bioscience's scientific excellence initiatives. "Leon's appointment reinforces Crown Bioscience's dedication to innovation and commitment to providing the highest quality therapeutic technology services," said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. "His extensive scientific and operational experience will serve Crown Bioscience well as we expand to meet the growing needs of preclinical research to the global

Blackbird Energy Inc. annonserer utnevnelsen av Allan Dixon som sjef for bedriftsutvikling23.8.2017 12:02Pressemelding

CALGARY, Alberta, 23. aug. 2017 (GLOBE NEWSWIRE) - Blackbird Energy Inc. (TSX-V:BBI) («Blackbird») har gleden av å kunngjøre utnevnelsen av Allan Dixon som sjef for bedriftsutvikling.  I denne rollen vil Dixon være ansvarlig for investorrelasjoner, kommunikasjonsinitiativer og strategiske bedriftsbevissthetsprogrammer i Nord-Amerika og Europa. Dixon har en omfattende bakgrunn i Calgarys olje- og gassindustri med erfaring fra investorrelasjoner ved Birchcliff Energy Ltd., aksjeanalyse ved National Bank Financial og investeringsrelatert bankvirksomhet ved Tristone Capital. Dixon har en bachelorgrad i handelsfag med spesialisering innen finans fra Dalhousie University. «Jeg er veldig glad for å ønske Allan velkommen til Blackbird-teamet, og jeg ser frem til å jobbe med ham. Med sin varierte bakgrunn og erfaring med å jobbe med noen av verdens fremste innovatører i bransjen, har jeg den største tillit til at han vil være et verdifullt tilskudd til teamet vårt og en ressurs fo

International Body Positive Mentor, Arabella S. Ruby, Launches New Fashion Collection Under the Xehar Brand, Arabella by Xehar23.8.2017 12:00Pressemelding

Xehar's successful ambassador marketing campaign continues to drive online sales while spreading body positive messages among millennials around the world PLAYA VISTA, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Today Xehar launches their newest collection Arabella by Xehar, an edgy and contemporary plus size fashion line targeting progressive millennials. High demand for Xehar's custom clothing lines can be seen by the recent collection Laura by Xehar, which sold out in a record 10 days. Xehar has developed a proven method in creating collections inspired by Body Positive Mentors who have a significant social media following. A photo is available at "Customers appreciate authenticity, and we are seeing great results by sharing our products through our Body Positive Mentors," says Hadari Oshri, CEO and founder of Xehar. "We are actively searching for m

Nasdaq Offers Proprietary U.S. Equity Data Feeds from Equinix Data Center in London23.8.2017 09:11Pressemelding

NEW YORK and LONDON, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) has announced the availability of proprietary U.S. equity feeds from Equinix's London International Business Exchange(TM) (IBX®) data center - LD4 - located in Slough, U.K. As part of Nasdaq's efforts to bring U.S proprietary equities data to a larger audience, Nasdaq now offers Nasdaq TotalView and Nasdaq Basic from LD4. Nasdaq Basic combines Nasdaq Best Bid and Offer (QBBO), with either Nasdaq Last Sale (NLS), or Nasdaq Last Sale Plus (NLS Plus). "We continue to focus on working closely with our clients around the world in order to help them gain secure, efficient access to our markets," said Jeff Kimsey, Head of Global Data Products, Nasdaq. "Buy-and sell-side clients based in the U.K. can now access our U.S. data products directly from the exchange through the Equinix LD4 data center." This new Point of Presence (PoP) will allow firms direct access to U.S. mar

Real People Investment Holdings Limited: Nordic bondholders approved an extension of the standstill period in written procedure22.8.2017 20:47Pressemelding

Real People Investment Holdings Limited (the "Company") today announces the successful completion of a written procedure in relation to the Company's outstanding SEK 260,000,000 and NOK 135,000,000 senior unsecured callable bonds with ISINs SE0005392560 and NO0010689342 2013/2018. The Nordic bondholders  authorized the bondholders' agent to (i) consent to an extension of the last date of the Standstill Period (as defined in the Standstill Agreement referred to below) from no later than 31 August 2017 until no later than 30 November 2017, and (ii) approve that an addendum is made to the Standstill Agreement to the effect that the automatic termination of the Standstill Period upon certain events is qualified by the requirement that the Majority Standstill Creditors (as defined in the Standstill Agreement) also elects to terminate the Standstill Period (the "Proposal"). As previously communicated in press releases, the Real People Group is experiencing f

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom